Cure My Disease

Don't miss your cure!

 Log in / Sign up

Robotic lung biopsy system under Real-World scrutiny

NCT ID NCT06923774

Knowledge-focused Sponsor: Intuitive Surgical Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Aug 05, 2026 · Updated 4 times

Summary

This study is observing how well the Ion endoluminal system, a robotic tool, works for lung nodule biopsies and localization in everyday medical practice across Europe. Researchers will track 1,200 adults to see how often the tool correctly diagnoses lung nodules and how often complications like pneumothorax or bleeding occur. The goal is to gather real-world data, not to test a new treatment.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 1,200 people

The number the study aims to enrol. It can still change while the study runs.

Started

Sep 2025

Expected to finish

Oct 2029

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Patients planned for an elective lung nodule biopsy and/or localization procedure using the Ion endoluminal system as their standard of care

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Patient is aged 18 years or older at time of consent. * Patient is planned to undergo a lung lesion biopsy(s) and/or localization procedure(s) utilizing the Ion endoluminal system. * Patient is willing and able to give written informed consent for clinical study participation. Exclusion Criteria: * Patient is participating in an interventional research study or research study with investigational agents with an unknown safety profile that would interfere with participation in this study or study results. * Female patient that is pregnant or breast feeding as determined by standard site practices. * Patient is legally incapacitated or in a legal/court ordered institution or is part of a known vulnerable population, including but not limited to dependency on the sponsor, hospital or study doctor. * Patient is not willing to comply with post-procedure study participation requirements. * Investigator, in their professional opinion, has decided that it is in the patient's best interest to not participate in the clinical study.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Lung cancer are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

lung cancer lung neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Lung cancer Pulmonary nodule

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    7 sites in 4 countries. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • DGD Lungenklining Hemer

    NOT_YET_RECRUITING

    Hemer, 58675, Germany

  • Helios Dr. Horst Schmidt Kliniken

    NOT_YET_RECRUITING

    Wiesbaden, 65199, Germany

  • Helios Klinikum Emil von Behring

    RECRUITING

    Berlin, 14165, Germany

  • Hôpital Marie Lannelongue

    RECRUITING

    Le Plessis-Robinson, 92350, France

  • University College London Hospitals NHS Foundation Trust

    RECRUITING

    London, NW1 2BU, United Kingdom

  • Universitätsspital Zürich

    RECRUITING

    Zurich, 8091, Switzerland

  • Wythenshawe Hospital, Manchester University NHS Foundation Trust

    RECRUITING

    Manchester, M23 9LT, United Kingdom

More trials for these conditions

Other studies related to the condition(s) this trial covers.